Clinical Trials - Where are we Headed with COVID-19 Trials?
Summary
This report provides an overview of global COVID-19 clinical trials extracted from the GlobalData Pharma Intelligence Center on March 30, 2022. The purpose of this report is to provide insight into the overall clinical trial landscape for COVID-19 clinical trials, trials using vaccines versus therapeutics, trials impacted by COVID-19, and testing/vaccination data.
Scope
- The clinical trials data used for these analyses were extracted from GlobalData’s Clinical Trials Database. The data included clinical trials, which were captured in the database as of March 30, 2022. The trials were analyzed and segmented by all COVID-19 trials, trials using vaccines, trials using therapeutics, and all trials impacted due to the pandemic. An analysis was also completed on COVID-19 testing and vaccination data.
- Trends of COVID-19 trials by phase, sponsor type and status
- Geographical distribution of COVID-19 trials
- Comparison of COVID-19 trials by vaccines versus therapeutics
- Impact of COVID-19 of clinical trials
- COVID-19 testing and vaccination data
- Executive Summary
- Introduction
- Analysis of COVID-19 Clinical Trials
- COVID-19 Clinical Trials for Vaccines
- COVID-19 Clinical Trials for Therapeutics
- COVID-19 Testing and Vaccination Data
- Impact of COVID-19 on Clinical Trials
- Key Findings
- Appendix
- List of Tables
- Table 1: Top Countries in COVID-19 Key Stats
- List of Figures
- Figure 1: Impact of COVID-19
- Figure 2: Top Countries in COVID-19 Key Stats
- Figures 3 & 4: Over 2,000 Vaccines and Therapeutics Are in Development
- Figure 5: Number of COVID-19 Clinical Trials by Start Date, by Month
- Figure 6: Number of COVID-19 Clinical Trials, by Multinational vs. Single Country
- Figure 7: Single Country COVID-19 Clinical Trials, by Region & Phase
- Figure 8: Multinational Country COVID-19 Clinical Trials, by Region & Phase
- Figure 9: COVID-19 Clinical Trial Sites, by Region
- Figures 10 & 11: COVID-19 Clinical Trial Sites, by Country & State
- Figures 12 & 13: Number of COVID-19 Clinical Trials, by Phase & Status
- Figure 14: Endpoint Status for Completed COVID-19 Clinical Trials
- Figure 15: Top Reasons for Terminated Trials, by Phase
- Figure 16: Top Reason for Terminated Trials, by Sponsor Type
- Figure 17: Long COVID-19 Clinical Trials, by Trial Start Date
- Figures 18 & 19: Average Completed Trial Duration for Viral Infections in General vs. COVID-19, by Phase
- Figure 20: COVID-19 Clinical Trials by Vaccine, by Trial Start Date
- Figures 21 & 22: Vaccine COVID-19 Clinical Trials, by Phase & Status
- Figure 23: Vaccine COVID-19 Clinical Trials, by Sponsor Type
- Figure 24: Top Industry Sponsors for COVID-19 Vaccine Clinical Trials
- Figure 25: Top Non-Industry Sponsors for COVID-19 Vaccine Clinical Trials
- Figure 26: Upcoming Filings and Regulatory Approvals for COVID-19 Vaccines
- Figure 27: COVID-19 Therapeutic Clinical Trials, by Trial Start Date
- Figures 28 & 29: Therapeutic COVID-19 Clinical Trials, by Phase & Status
- Figure 30: Therapeutic COVID-19 Clinical Trials, by Sponsor Type
- Figure 31: Top Industry Sponsors for COVID-19 Therapeutic Clinical Trials
- Figure 32: Top Non-Industry Sponsors for COVID-19 Therapeutic Clinical Trials
- Figure 33: Upcoming 2022 Filings and Regulatory Approvals for Therapeutic COVID-19 Drugs
- Figure 34: Cumulative Number of COVID-19 Tests, by Country
- Figure 35: COVID-19 Tests Per Thousand People, by Country
- Figures 36 & 37: Cumulative Number of Fully Vaccinated People per 1M & Number of Vaccinations by Month per 1M, by Country
- Figure 38: Fully Vaccinated Population Rate, by Country
- Figures 39 & 40: Percent of Population Received One Dose & Percent of Population Received Second Dose, by Country
- Figure 41: US COVID-19 Vaccination Administration by Vaccine Type vs. Number of People Fully Vaccinated per 1M
- Figure 42: Percent of People in the US Who Received Booster Shoes, by Primary Booster Type
- Figure 43: Clinical Trials Disrupted Due to COVID-19
- Figures 44 & 45: Disrupted Clinical Trials, by Reason
- Figure 46: Disrupted Clinical Trials, by Therapy Area
- Figure 47: Disrupted Clinical Trials Relative to Ongoing and Planned Trials, by Therapy Area
- Figures 48 & 49: Disrupted Clinical Trials Activities, by Region & Country
- Figure 50: Disrupted Clinical Trials, by Top Sponsors
- Figure 51: Resumed Clinical Trials After Being Disrupted Due to COVID-19
- Figure 52: Percent of Decentralized Clinical Trials, By Start Year
- Figure 53: Virtual Components Used In Decentralized Clinical Trials
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook